disease.sh - Open Disease Data
Sourced data from Johns Hopkins University, the
New York Times, Worldometers, and Apple reports to give you a
comprehensive view of the data.
Developed by Vicente G. Reyes
A Self-Directed Learner, a Freelance Web Developer, a Volunteer Developer at Project Website, Moderator at DEV,
& a Podcast host. www.vgreyes.com
Date published: 2021-06-09
While work on COVID-19 vaccine boosters is already underway, one expert warned that emerging variants threaten to create a "window of susceptibility," which without therapeutics could lead to more virus-inflicted death.
Date published: 2021-04-24
Sorrento Therapeutics (NASDAQ:SRNE) and Eiger BioPharmaceuticals (NASDAQ:EIGR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk. Volatility and Risk Sorrento Therapeutics has a beta of 2.7, meaning that its share price is []
Date published: 2021-04-22
A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure.
Date published: 2021-04-19
Qualigen Therapeutics Inc (NASDAQ: QLGN) was one of the sponsors for the Benzinga Biotech Global Small Cap Conference that took place on March 24-25, 2021. ...
Date published: 2021-03-25
VANCOUVER, BC, March 25, 2021 /PRNewswire/ -- USA News Group - Rollouts of two approved COVID-19 vaccines have for the past few months started making their way into markets around
Date published: 2021-03-09
A San Diego company says it's leading the charge in the race to get ahead of dangerous COVID-19 variants.
Date published: 2021-03-09
The delay of Sorrento Therapeutics Covid-19 vaccine has weakened SRNE stock, but the company has plenty more in the pipeline.
Date published: 2021-03-06
Revive Therapeutics Ltd stock and Drug Manufacturers - Major market discussion, news, and analysis from Canada's largest community of active investors
Date published: 2021-03-03
Moderna (NASDAQ:MRNA) and Sorrento Therapeutics (NASDAQ:SRNE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership. Analyst Ratings This is a breakdown of recent ratings and target prices for Moderna and Sorrento Therapeutics, []
Date published: 2021-02-25
The deal values Pandion, which is developing drugs to target autoimmune diseases, at about $1.85 billion.
